CL2008002828A1 - Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno. - Google Patents

Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.

Info

Publication number
CL2008002828A1
CL2008002828A1 CL2008002828A CL2008002828A CL2008002828A1 CL 2008002828 A1 CL2008002828 A1 CL 2008002828A1 CL 2008002828 A CL2008002828 A CL 2008002828A CL 2008002828 A CL2008002828 A CL 2008002828A CL 2008002828 A1 CL2008002828 A1 CL 2008002828A1
Authority
CL
Chile
Prior art keywords
amount greater
alisquiren
filler
salts
acid phosphate
Prior art date
Application number
CL2008002828A
Other languages
English (en)
Inventor
Jean-Claude Bianchi
Heiko Busies
Andreas Meyer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008002828A1 publication Critical patent/CL2008002828A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de dosificación oral sólida que comprende alisquireno en una cantidad mayor a 38% en peso con relación al peso total; proceso de preparación y su uso en enfermedades cardiovasculares como hipertensión, insuficiencia cardiaca, miopatía cardiaca, entre otras.
CL2008002828A 2007-09-28 2008-09-24 Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno. CL2008002828A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97589407P 2007-09-28 2007-09-28

Publications (1)

Publication Number Publication Date
CL2008002828A1 true CL2008002828A1 (es) 2009-05-15

Family

ID=40377181

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002828A CL2008002828A1 (es) 2007-09-28 2008-09-24 Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.

Country Status (22)

Country Link
US (1) US20110033533A1 (es)
EP (2) EP2205232A2 (es)
JP (1) JP5378384B2 (es)
KR (1) KR20100076996A (es)
CN (1) CN101808630A (es)
AR (1) AR068539A1 (es)
AU (1) AU2008303504C1 (es)
BR (1) BRPI0817586A2 (es)
CA (1) CA2697229A1 (es)
CL (1) CL2008002828A1 (es)
CO (1) CO6270216A2 (es)
GT (1) GT201000064A (es)
MA (1) MA31768B1 (es)
MX (1) MX2010003260A (es)
MY (1) MY148266A (es)
NZ (1) NZ584005A (es)
PE (1) PE20091203A1 (es)
RU (1) RU2483718C2 (es)
TN (1) TN2010000120A1 (es)
TW (1) TWI436760B (es)
WO (1) WO2009040373A2 (es)
ZA (1) ZA201001144B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100135936A (ko) * 2008-05-23 2010-12-27 테바 파마슈티컬 인더스트리즈 리미티드 알리스키렌 모노푸마레이트 및 이의 제조 방법
AR080683A1 (es) 2010-03-16 2012-05-02 Novartis Ag Composiciones farmaceuticas de aliskiren y metodos de administracion
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382969A1 (en) 2010-04-30 2011-11-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multicoated Aliskiren formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
RU2183116C1 (ru) * 2001-07-10 2002-06-10 Жаров Олег Владимирович Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
PE20142101A1 (es) * 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
US20090247582A1 (en) * 2005-04-27 2009-10-01 Randy Lee Webb Methods of treating atherosclerosis
KR20080066776A (ko) * 2005-11-08 2008-07-16 노파르티스 아게 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
MX2009004628A (es) * 2006-11-09 2009-05-15 Novartis Ag Sal de alisquireno con acido orotico.
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
US20100209480A1 (en) * 2007-09-28 2010-08-19 Ralf Altenburger Galenical formulations of organic compounds

Also Published As

Publication number Publication date
US20110033533A1 (en) 2011-02-10
EP2548553A1 (en) 2013-01-23
RU2010116530A (ru) 2011-11-10
MY148266A (en) 2013-03-29
CN101808630A (zh) 2010-08-18
WO2009040373A2 (en) 2009-04-02
ZA201001144B (en) 2011-12-28
PE20091203A1 (es) 2009-09-11
TW200922546A (en) 2009-06-01
AR068539A1 (es) 2009-11-18
MX2010003260A (es) 2010-04-29
AU2008303504C1 (en) 2013-05-16
CO6270216A2 (es) 2011-04-20
NZ584005A (en) 2012-08-31
AU2008303504A1 (en) 2009-04-02
TN2010000120A1 (en) 2011-09-26
WO2009040373A3 (en) 2009-08-20
GT201000064A (es) 2012-03-30
JP5378384B2 (ja) 2013-12-25
RU2483718C2 (ru) 2013-06-10
EP2205232A2 (en) 2010-07-14
TWI436760B (zh) 2014-05-11
AU2008303504B2 (en) 2012-03-22
BRPI0817586A2 (pt) 2015-03-31
KR20100076996A (ko) 2010-07-06
JP2010540489A (ja) 2010-12-24
CA2697229A1 (en) 2009-04-02
MA31768B1 (fr) 2010-10-01

Similar Documents

Publication Publication Date Title
ES2535839T3 (es) Composición de un gel que comprende pectina ligeramente metoxilada
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX2011008171A (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
ECSP11011095A (es) Amidas del ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico sustituidas como moduladores de KCNQ2/3.
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
AR070356A1 (es) Producto para cuidado oral y metodos de uso del mismo
CY1115043T1 (el) Φαρμακευτικο σκευασμα
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
BR112013028534A2 (pt) compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
PE20091809A1 (es) Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
CY1123398T1 (el) Συνθεση συνδυασμου
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
ECSP13012667A (es) Compuestos de triazolopiridina
AR079639A1 (es) Composicion de pasta de dientes anti-erosiva
AR053803A1 (es) Uso de acido pinolenico
NI201100149A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia.
ECSP13012453A (es) 2-oxi-quinolina-3-carboxamidas sustituidas como moduladores KCNQ2/3
CY1115955T1 (el) Ενα στερεο φαρμακευτικο σκευασμα
SV2010003701A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
CL2008002828A1 (es) Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso